RT Book, Section
A1 Dixon, Dave L.
A1 Riche, Daniel M.
A1 Kelly, Michael S.
A2 DiPiro, Joseph T.
A2 Yee, Gary C.
A2 Haines, Stuart T.
A2 Nolin, Thomas D.
A2 Ellingrod, Vicki L.
A2 Posey, L. Michael
SR Print(0)
ID 1205561521
T1 Dyslipidemia
T2 DiPiro’s Pharmacotherapy: A Pathophysiologic Approach, 12th Edition
YR 2023
FD 2023
PB McGraw Hill
PP New York, NY
SN 9781264264544
LK accesspharmacy.mhmedical.com/content.aspx?aid=1205561521
RD 2024/04/23
AB Update  SummaryJuly,  2023The  following  sections,  tables,  and  figures  were  updated:The  chapter  has  been  revised  in  several  sections  to  reflect  the  results  of  the  CLEAR-OUTCOMES  study,  which  provides  evidence  regarding  the  potential  role  of  bempedoic  acid  in  the  prevention  of  cardiovascular  events.  Revisions  include  updates  to  the  following  sections:General  Approach  to  TreatmentTable  32-3  Select  Landmark  Clinical  TrialsAdenosine  Triphosphate-Citrate  Lyase  InhibitorsA  new  paragraph  was  added  to  the  “Dietary  Supplements”  section  reflecting  the  results  of  the  SPORT  trial  which  compared  rosuvastatin  to  six  commonly  used  dietary  supplements.Updates  were  made  throughout  the  chapter  to  change  PCSK9  inhibitors  to  the  preferred  terminology  PCSK9  monoclonal  antibody  (PCSK9  mAb),  including  Figure  32-7.Revisions  are  done  to  Figure  32-8  clarifying  the  approach  to  treatment  of  hypertriglyceridemia.Information  is  added  about  the  nocebo  effect  and  how  to  mitigate  it  in  the  “HMG-CoA  Reductase  Inhibitors”  (Statins)  section.The  REPRIEVE  study  provides  new  evidence  regarding  the  benefits  of  statin  therapy  in  patients  with  human  immunodeficiency  virus  (HIV)  infection;  updates  were  made  to  the  “Patients  with  Chronic  Inflammatory  Disorders  and  HIV”  section.